PFNX

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of Evert (Eef) Schimmelpennink to its Board of Directors. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development, commercial growth, manufacturing, and business development. "I am pleased to welcome Eef Schimmelpennink to Pipeline's Board of Directors," said Carmine Stengone, President and Chief Executive Officer of Pipeline Therapeutics. "Eef is a renowned leader in the life-sciences industry whose cross-functional leade

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics today announced that it has recently elected a Chairman of its Board of Directors, appointed two new Independent Directors to the Board, and appointed a new member to its Advisory Board. Philippe Calais, Pharm D, Ph.D., President, Chief Executive Officer and a director of MatriSys Bioscience, Inc., has been elected Chairman of the Board of Directors of TransCode. Dr. Calais has served on TransCode’s Board of Directors since October 2018. With an extensive background in drug development, Dr. Calais’ experience has been instrumental in advancing TransCode’s lead therapeutic candidate, TTX-MC138, focused on treating metastatic cancer. T

SC 13G/A - Pfenex Inc. (0001478121) (Subject)

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE: PFNX) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of PFNX to Ligand Pharmaceuticals Incorporated. If you are a PFNX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Proteostasis Therapeutics, Inc. (NASDAQ: PTI) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of PTI with Yumanity Therapeutics. If you are a PTI invest

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating: Maxim Integrated Products, Inc. (NASDAQ: MXIM) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Analog Devices, Inc. Under the terms of the agreement, Maxim stockholders will receive 0.630 of a share of Analog Devices common stock for each share of Maxim common stock they hold at closing. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/maxim-integrated-products-inc-mxim-stock-merger-analog-devices-adi/. Jernigan Capital, Inc. (NYSE: JCAP) concerning potential violations